

## Ghana Support for Pentavalent Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Ghana			
<b>2. Grant number:</b> 1719-GHA-04c-X			
<b>3. Date of Decision Letter:</b> 19 March 2019			
<b>4. Date of the Partnership Framework Agreement:</b> 11 July 2014			
<b>5. Programme title:</b> New Vaccine Support (NVS), Pentavalent Routine			
<b>6. Vaccine type:</b> Pentavalent			
<b>7. Requested product presentation and formulation of vaccine:</b> DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
<b>8. Programme duration<sup>1</sup>:</b> 2002 -2019			
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)			
	2002-2018	2019	Total <sup>2</sup>
Programme Budget (US\$)	US\$96,831,772 <sup>3</sup>	US\$1,386,500	US\$98,218,272
<b>10. Vaccine introduction grant (in US\$):</b>			
US\$ 100,000 disbursed was on 11 February 2002			
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>			
Type of supplies to be purchased with Gavi funds in each year	2002-2018	2019	
Number of Pentavalent vaccines doses		1,948,500	
Annual Amounts (US\$)	US\$96,831,772 <sup>5</sup>	US\$1,386,500	
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.			

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<b>13. Self-procurement:</b> Not applicable															
<p><b>14. Co-financing obligations:</b> Reference code: 1719-GHA-04c-X-C</p> <p>According to the co-financing policy, the Country falls within the group Preparatory transition.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2019</td> </tr> <tr> <td>Number of vaccine doses</td> <td>811,500</td> </tr> <tr> <td>Number of AD syringes</td> <td>772,000</td> </tr> <tr> <td>Number of re-constitution syringes</td> <td></td> </tr> <tr> <td>Number of safety boxes</td> <td>8,500</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$559,808</td> </tr> <tr> <td>Total co-financing payments (US\$) (including freight)</td> <td>US\$612,500</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2019	Number of vaccine doses	811,500	Number of AD syringes	772,000	Number of re-constitution syringes		Number of safety boxes	8,500	Value of vaccine doses (US\$)	US\$559,808	Total co-financing payments (US\$) (including freight)	US\$612,500
Type of supplies to be purchased with Country funds in each year	2019														
Number of vaccine doses	811,500														
Number of AD syringes	772,000														
Number of re-constitution syringes															
Number of safety boxes	8,500														
Value of vaccine doses (US\$)	US\$559,808														
Total co-financing payments (US\$) (including freight)	US\$612,500														
<b>15. Operational support for campaigns:</b> Not applicable															
<p><b>16. Additional reporting requirements:</b> Not applicable</p> <table border="1"> <thead> <tr> <th>Reports and information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td> <p>31 March 2019</p> <p>15 May 2019</p> </td> </tr> <tr> <td> <p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p> </td> <td> <p>To be agreed with Secretariat</p> </td> </tr> </tbody> </table>		Reports and information	Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>	<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>								
Reports and information	Due dates														
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	<p>31 March 2019</p> <p>15 May 2019</p>														
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>														
<b>17. Financial clarifications:</b> Not applicable															
<b>18. Other conditions:</b> Not applicable															

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
19 March 2019